Oncology

The new BiTE antibody technology developed by the company can simultaneously engage 2 different targets, which can help recruit T-cells to malignant cells, and will be evaluated in ALL patients.

The approval follows 2 clinical trials evaluating the regimen in 1720 cancer patients receiving chemotherapy.

The approval extends the use of bortezomib beyond relapsed and refractory patients.

The identification of specific RNA molecules in the urine of individuals with prostate cancer raises hope for a non-invasive test for the disease.

Having decided to restrict the distribution of 3 of its top-selling oncology medications, Avastin, Rituxan, and Herceptin only through specialty pharmacies, Genentech is witnessing protests in various forms from healthcare centers.

The collaboration between med fusion and GenomOncology promises improved outcomes in personalized cancer trials.

A Taiwan study found a significantly reduced risk of cancer among RA patients on biologics.

Results of a large study performed across cancer centers in Germany, published online October 6, 2014 in the Journal of Clinical Oncology, show that 32% of people with cancer experienced some form of clinically relevant mental health challenge, such as anxiety, depressive and adjustment disorders.

Peter B. Bach, MD, MAPP, Memorial Sloan Kettering Cancer Center, writes in the Journal of the American Medical Association that cancer drugs could be charged different prices by indication, since the value for patients varies. His article appeared days before an appearance on 60 Minutes to discuss the high price of cancer drugs.

Combining nivolumab, an immuno-oncology molecule, with 1 of 3 targeted agents from Novartis is expected to improve patient response in NSCLC.

Chemotherapy drugs, which could be poisons, can result in adverse health outcomes in healthcare workers who administer them to patients without adequate safety measures.

Sunesis Pharmaceuticals announced the failure of a phase 3 study Monday morning. The company's experimental drug vosaroxin did not extend survival of elderly patients with advanced acute myeloid leukemia compared to a placebo.

A study published in the American Journal of Preventive Medicine found that lack of awareness resulted in women over 65 and those who had undergone hysterectomy routinely undergoing a Pap test.